bg-img9.jpg
8.jpg
The Evolution of Public Health Research: The Next Frontier

In the first episode of our series, we looked at the cholera epidemic and how public health emerged as a corollary to the germ theory of disease. In this final episode, we arrive at what may be the next frontier in public health research, and once again we are chasing microbes.

Topic: Public Health Research, Content: Blog

Proposed Changes to Biospecimen Consent Requirements Dropped from the Revised Common Rule

If you are conducting biospecimen-based research, you are probably aware that on January 18, the long-anticipated revised Common Rule (Title 45 of the CFR, part 46, Federal Policy for the Protection of Human Subjects) was posted to the Federal Register (for some background on the nature of these revisions, see my blog post).

Topic: Biobanking and Biorepository, Topic: Public..........

A Perspective on "Expanded Access" to Experimental (Cell) Therapies

“Expanded Access,” is a regulatory pathway for physicians to gain access to experimental therapies for patients who usually do not qualify for the clinical trial. This pathway often represents one final chance against a condition that is severely debilitating and/or fatal. Often called “Compassionate Use,” the number of patients and physicians requesting access to experimental therapies has been growing steadily over the past three decades.

Topic: Cold-Chain Logistics, Topic: Cell Therapy S..........

Entrusting Your Biologics with a Service Provider? Important Factors to Consider

Over the past decade, a wave of scientific advances and new technologies have made significant impacts on how medicines are discovered. The drive towards personalized medicine has led to an increased understanding of the molecular and genetic bases of disease. As a result of this increased knowledge, the life sciences industry is shifting its focus from small molecule medicine to biologic medicine, resulting in increased use of biologics in clinical trials and R&D efforts.

Topic: GMP Biologics Management, Content: Blog

Phacilitate Cell and Gene Therapy World 2017: Streamline the path from discovery to cure


The advancements in cell and gene therapy are increasing at a rapid pace and are transforming the way we think about medicine. Whether in research or in the clinic, scientific innovators are acutely aware that every moment counts when working with these valuable therapies. To facilitate knowledge sharing and collaboration, Thermo Fisher Scientific is proud to support Phacilitate Cell & Gene Therapy World 2017 as the Platinum Sponsor.

Topic: Cell Therapy Solutions, Content: Blog

The Evolution of Public Health Research: Malaria, Part 2

Malaria Elimination vs. Eradication, and Genetic Diversity vs. “Freezer Epidemiology”

It is because of its historic mission to eliminate malaria that the CDC is in Atlanta, Georgia. The agency is still deeply involved with the control of malaria, by providing technical assistance around the world, and continuing to protect the US population from the parasite. The CDC estimates that 1,500 people in the USA annually are infected with malaria while traveling, and the CDC tracks these cases and advises the medical community on accurate diagnosis and treatment.

Topic: Public Health Research, The Evolution of Pu..........

Fisher BioServices Top Five Most Popular Blogs of 2016

2016 has been a year filled with new discoveries in the health and medical R&D space. Through our blog, we have shared great stories of our customers' work and discussed a wide-breadth of topics, focusing on cell therapies, biological material, and public health research.

Content: Blog

The Evolution of Public Health Research: Malaria, Part 1

Mosquitoes, the Military, and Why the CDC is in Atlanta

To most of us in the US, malaria is a health problem restricted to distant parts of the globe. Even in the international media, the disease receives little attention. However, it has only been since 1949 that Malaria was declared “eliminated” in the US.

Topic: Public Health Research, The Evolution of Pu..........

Cell Therapy Manufacturing & Gene Therapy Congress

We are pleased to announce our participation as a sponsor at the upcoming Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam. The event will focus on connecting cell and gene therapy leads to drive manufacturing and commercialization through direct access to innovative discovery, product development and regulatory know-how. We are honored to showcase our global integrated solution for cell therapy clinical and commercial development in conjunction with our parent company, Thermo Fisher Scientific.

Topic: Cell Therapy Solutions, Content: Blog

ISBER Regional Meeting: Quality Biobanking for Precision Research and Medicine

We are pleased to announce our participation at the International Society for Biological and Environmental Repositories (ISBER) 2016 Regional Meeting in Bethesda, Maryland on November 7-8. This year's theme, Quality Biobanking for Precision Research and Medicine, will focus on overcoming scientific, information technology and policy challenges. This regional event allows for greater opportunity for interactions between attendees and a focus on regional issues.

Topic: Biobanking and Biorepository, Topic: Public..........

Decentralized Manufacture: The Drivers and Barriers

The emergence of advanced therapeutics, including cell and gene-based therapies (CGTs), presents significant opportunities for treating unmet clinical needs, and specifically, has demonstrated the potential to provide personalized therapies. Amidst the exciting science and clinical opportunities however, there are unique challenges that arise from manufacturing and delivering patient-specific CGTs.

Topic: Cell Therapy Solutions, Content: Blog

An Alternative Model for Clinical Trial Product Management: Exploring Distribution and Dispensing

Managing limited supplies of an investigational agent in a clinical trial can present challenges. The typical practice is to ship inventory to the research pharmacy or the principal investigator’s office at clinical a site in anticipation of enrollment. One challenge is that the amount needed at study sites can only be estimated, and inadequate inventory may delay the study while providing extra is expensive and wasteful. In the meantime, the agent(s) and clinical supplies sit in storage until enrollment proceeds and dispensing begins. This ties up inventory and can create additional challenges with expiration dates. However, there is an alternative model of clinical trial support for consideration.

Topic: Clinical Trial Sample Management, Content: ..........